Alpha-Synuclein(SNCA)antibody

Alpha-Synuclein(SNCA)antibody
Cat.#: 2016-1
Rabbit Monoclonal Antibody
Clone ID: EP1646Y
Swiss Prot: P37840
Mol Weight: 18kDa
Size: 100ul

Description
Alpha-Synuclein is expressed predominantly in brain, where it is concentrated in presynaptic nerve terminals (1). The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Phosphorylation of alpha-synuclein at Ser 129 promoted fibril formation in vitro and these results highlight the importance of phosphorylation of filamentous proteins in the pathogenesis of neurodegenerative disorders (2). Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin. It is hypothesized that parkin and alpha-synculein interact functionally, namely, that parkin ubiquitinates alpha-synuclein normally and that this process is altered in autosomal recessive PD (3).

Recommended Applications
WB, ICC

Applications and Recommended Dilution Factors
WB: 1:1,000 - 10,000
ICC: 1:50 - 100

Species Reactivity
Human, Mouse, Rat

Cross reactivity determined by western blot only.

Products Data 

Specificity
A synthetic peptide corresponding to residues on the N-terminus of human Alpha-synuclein was used as an immunogen.

Storage Condition and Buffer
Store at -20 °C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.

Alternative Names
SNCA antibody, MGC110988 antibody, NACP antibody, PARK1 antibody, PARK4 antibody, PD1 antibody, Alpha-synuclein antibody, Non-A beta component of AD amyloid antibody, Non-A4 component of amyloid precursor antibody

Description References
1. Jakes R, et al. FEBS Lett. 345(1):27-32, 1994.
2. Fujiwara H, et al. Nat Cell Biol 4(2):160-4, 2002.
3. Shimura H, et al. Science 293(5528):263-9, 2001.

Product References
1. Qing H, Wong W, McGeer EG, et al, Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications ,Biochem Biophys Res Commun 387 (2009) 149-52
[Application: WB]